Next Article in Journal
“This is a kind of Betrayal”: A Qualitative Study of Disability after Breast Cancer
Previous Article in Journal
Screening for Prostate Cancer: Controversy? What Controversy?
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Hormone Replacement Therapy and Outcomes for Women with Non-Small-Cell Lung Cancer: Can An Association be Confirmed?

Andrew Robinson, Regional Cancer Program, Sudbury Regional Hospital, 41 Ramsey Lake Road, Sudbury, ON P3E 5J1, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(3), 21-25; https://doi.org/10.3747/co.v16i4.465
Submission received: 5 February 2009 / Revised: 4 March 2009 / Accepted: 10 April 2009 / Published: 1 May 2009

Abstract

Background: A recent report suggested that women who had been taking hormone replacement therapy (hrt) experienced significantly decreased survival after a lung cancer diagnosis. Given the large cohort of women who have received hrt, it is important to try to confirm that association. Methods: We reviewed female patients diagnosed with lung cancer at our institution between January 1999 and December 2003 for age at diagnosis, disease stage, treatment, smoking history, hrt, performance status, weight loss, age at menopause, and overall survival. Patients were excluded if they had small-cell lung cancer or an unknown primary cancer, or if they had had previous or synchronous non-lung, non-skin cancers. Statistical analysis used the chi-square test for categorical variables and the Kaplan–Meier method and Cox regression model for univariate and multivariate analyses of overall survival. Results: Of 397 eligible patients, most (68%) were stage iii or iv. The group included very few never-smokers (5%). The proportion of patients with experience of prior or current hrt was 29%, and no effect on overall survival was observed. Median survival was 13 months in the non-hrt group and 14 months in the hrt group. Significant factors predicting for overall survival included performance status, stage, and weight loss. Conclusions: Stage, performance status, and weight loss are the most powerful predictors of survival for women with non-small-cell lung cancer. As compared with non-hrt users, patients with prior hrt use did not have inferior outcomes, failing to duplicate previously published results.
Keywords: sex; lung cancer; hormone therapy; prognostic factors sex; lung cancer; hormone therapy; prognostic factors

Share and Cite

MDPI and ACS Style

Ayeni, O.; Robinson, A. Hormone Replacement Therapy and Outcomes for Women with Non-Small-Cell Lung Cancer: Can An Association be Confirmed? Curr. Oncol. 2009, 16, 21-25. https://doi.org/10.3747/co.v16i4.465

AMA Style

Ayeni O, Robinson A. Hormone Replacement Therapy and Outcomes for Women with Non-Small-Cell Lung Cancer: Can An Association be Confirmed? Current Oncology. 2009; 16(3):21-25. https://doi.org/10.3747/co.v16i4.465

Chicago/Turabian Style

Ayeni, O., and Andrew Robinson. 2009. "Hormone Replacement Therapy and Outcomes for Women with Non-Small-Cell Lung Cancer: Can An Association be Confirmed?" Current Oncology 16, no. 3: 21-25. https://doi.org/10.3747/co.v16i4.465

Article Metrics

Back to TopTop